Fig. 6
From: Computational inference of cancer-specific vulnerabilities in clinical samples
Experimental validation of predicted vulnerabilities by apoptosis and cell proliferation measurements. a Scatter plots showing the distribution of Annexin V and BrdU staining, which marks apoptosis and cell proliferation, respectively, for two patient-derived cells with positive predicted dependency on RAN, namely, PD(+)RAN-1 and PD(+)RAN-2, before and after RAN inactivation by CRISPR-Cas9. Shown here are day 7 results. Plots for days 3 and 5 are provided in Additional file 1: Figure S7. The graphs on the right indicate the percentage of Annexin V- or BrdU-positive cells according to days. b, c Scatter plots showing the distribution of Annexin V and BrdU staining for patient-derived cells with positive or negative predicted dependency on b XRCC6 and c PSMB4 before and after CRISPR-Cas9 knockout. Shown here are day 7 results for PD(+)XRCC6-1, PD(−)XRCC6-1, PD(+)PSMB4-1, and PD(−)PSMB4-1. Plots for days 3 and 5 after inactivation in these cells, and data for days 3, 5, and 7 after inactivation in PD(+)XRCC6-2, PD(−)XRCC6-2, PD(+)PSMB4-2, and PD(−)PSMB4-2 are provided in Additional file 1: Figures S8~S9. The graphs on the right indicate the percentage of Annexin V- or BrdU-positive cells according to days after inactivation